NDLI: Clinical outcomes of early remdesivir administration in hospitalized patients at high risk for severe COVID-19 during the Omicron wave

Content Provider	Springer Nature : BioMed Central
Author	La, Yeon Ju Oh, Won Sup Kim, Changhyup Lim, Myoung-nam Jeon, Yong Duk
Abstract	Background Early remdesivir administration in high-risk patients with coronavirus disease 2019 (COVID-19) is known to be effective in preventing the progression to severe disease. However, the effect of early remdesivir administration on Omicron variants, which are known to have decreased severity, remains unclear. Methods This study aimed to analyze the effects of early remdesivir administration during the Omicron wave in hospitalized patients. Electronic medical records of hospitalized patients with confirmed COVID-19 between February 2022 and February 2023 were reviewed. We included patients aged ≥ 18 years who had symptom onset within 7 days and had at least one risk factor for disease progression at the time of diagnosis. We compared the clinical outcomes between the early remdesivir administration group and the group not administered early remdesivir. The primary outcome was all-cause mortality within 28 days and the secondary outcome was the need for oxygen supplementation within 28 days. Multivariable analysis was conducted to assess risk factors for all-cause mortality and the need for oxygen supplementation. Results A total of 286 patients were enrolled, including 88 in the early remdesivir administration group and 198 in the control group. Clinical outcomes, including all-cause mortality (3.4% vs. 6.1%, P = 0.556) and need for oxygen supplementation (15.9% vs. 14.6%, P = 0.783) within 28 days, were not significantly different between the two groups. Age (HR, 1.061; 95% CI: 1.002, 1.124; P = 0.043), BMI (HR, 0.849; 95% CI: 0.725, 0.994; P = 0.041), and malignancy (HR, 4.619; 95% CI: 1.618, 13.189; P = 0.004) were identified as independent factors associated with all-cause mortality. Additionally, BMI (OR, 0.908; 95% CI, 0.824, 1.000; P = 0.049) and vaccination with more than three doses (OR, 0.412; 95% CI, 0.202, 0.839; P = 0.015) were independent factors associated with the need for oxygen supply. Early remdesivir administration was not significantly associated with all-cause mortality (HR, 0.393; 95% CI: 0.109, 1.417; P = 0.154) or the need for oxygen supplementation (OR, 0.823; 95% CI: 0.389, 1.740; P = 0.610). Conclusions In our study, early remdesivir administration was not associated with preventing progression to severe disease when used as previously indicated during the Omicron wave. Considering the decline in the severity of the Omicron variant and the increased vaccination rate reported in previous studies, further studies are needed to establish new indications for the use of early remdesivir in the Omicron variant.
Related Links	https://bmcinfectdis.biomedcentral.com/counter/pdf/10.1186/s12879-025-10585-3.pdf
Ending Page	7
Page Count	7
Starting Page	1
File Format	HTM / HTML
ISSN	14712334
DOI	10.1186/s12879-025-10585-3
Journal	BMC Infectious Diseases
Issue Number	1
Volume Number	25
Language	English
Publisher	BioMed Central
Publisher Date	2025-02-05
Access Restriction	Open
Subject Keyword	Infectious Diseases Parasitology Medical Microbiology Tropical Medicine Internal Medicine COVID-19 Omicron Early remdesivir Severity
Content Type	Text
Resource Type	Article
Subject	Infectious Diseases
Journal Impact Factor	3.4/2023
5-Year Journal Impact Factor	3.3/2023

Sl.	Authority	Responsibilities	Communication Details
1	Ministry of Education (GoI), Department of Higher Education	Sanctioning Authority	https://www.education.gov.in/ict-initiatives
2	Indian Institute of Technology Kharagpur	Host Institute of the Project: The host institute of the project is responsible for providing infrastructure support and hosting the project	https://www.iitkgp.ac.in
3	National Digital Library of India Office, Indian Institute of Technology Kharagpur	The administrative and infrastructural headquarters of the project	Dr. B. Sutradhar bsutra@ndl.gov.in
4	Project PI / Joint PI	Principal Investigator and Joint Principal Investigators of the project	Dr. B. Sutradhar bsutra@ndl.gov.in Prof. Saswat Chakrabarti will be added soon
5	Website/Portal (Helpdesk)	Queries regarding NDLI and its services	support@ndl.gov.in
6	Contents and Copyright Issues	Queries related to content curation and copyright issues	content@ndl.gov.in
7	National Digital Library of India Club (NDLI Club)	Queries related to NDLI Club formation, support, user awareness program, seminar/symposium, collaboration, social media, promotion, and outreach	clubsupport@ndl.gov.in
8	Digital Preservation Centre (DPC)	Assistance with digitizing and archiving copyright-free printed books	dpc@ndl.gov.in
9	IDR Setup or Support	Queries related to establishment and support of Institutional Digital Repository (IDR) and IDR workshops	idr@ndl.gov.in

Real-world evaluation of early remdesivir in high-risk COVID-19 outpatients during Omicron including BQ.1/BQ.1.1/XBB.1.5

Impact of vaccination status on clinical outcomes of hospitalized COVID-19 patients

Characteristics and outcomes of COVID-19 patients during the BA.5 omicron wave in Tehran, Iran: a prospective observational study

Real-world evidence of remdesivir in formerly hospitalized COVID-19 patients: patient-reported and functional outcomes

Epidemiological and clinical risk factors related to severe COVID-19 in Iran: a multi-center study

Clinical characteristics and risk factors for a prolonged length of stay of patients with asymptomatic and mild COVID-19 during the wave of Omicron from Shanghai, China

Correction to: Characteristics and outcomes of COVID-19 patients during the BA.5 omicron wave in Tehran, Iran: a prospective observational study

Association between asthma and COVID-19 severity during Omicron epidemic: a retrospective cohort study using real-world data

Clinical features and outcomes of hospitalized patients with COVID-19 during the Omicron wave in Shanghai, China.

Clinical outcomes of early remdesivir administration in hospitalized patients at high risk for severe COVID-19 during the Omicron wave

Similar Documents

Real-world evaluation of early remdesivir in high-risk COVID-19 outpatients during Omicron including BQ.1/BQ.1.1/XBB.1.5

Impact of vaccination status on clinical outcomes of hospitalized COVID-19 patients

Characteristics and outcomes of COVID-19 patients during the BA.5 omicron wave in Tehran, Iran: a prospective observational study

Real-world evidence of remdesivir in formerly hospitalized COVID-19 patients: patient-reported and functional outcomes

Epidemiological and clinical risk factors related to severe COVID-19 in Iran: a multi-center study

Clinical characteristics and risk factors for a prolonged length of stay of patients with asymptomatic and mild COVID-19 during the wave of Omicron from Shanghai, China

Correction to: Characteristics and outcomes of COVID-19 patients during the BA.5 omicron wave in Tehran, Iran: a prospective observational study

Association between asthma and COVID-19 severity during Omicron epidemic: a retrospective cohort study using real-world data

Clinical features and outcomes of hospitalized patients with COVID-19 during the Omicron wave in Shanghai, China.

Clinical outcomes of early remdesivir administration in hospitalized patients at high risk for severe COVID-19 during the Omicron wave